A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys
-
Published:2017-11-09
Issue:1
Volume:7
Page:
-
ISSN:2044-5040
-
Container-title:Skeletal Muscle
-
language:en
-
Short-container-title:Skeletal Muscle
Author:
St. Andre Michael,Johnson Mark,Bansal Prashant N.,Wellen Jeremy,Robertson Andrew,Opsahl Alan,Burch Peter M.,Bialek Peter,Morris Carl,Owens Jane
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Molecular Biology,Orthopedics and Sports Medicine
Reference39 articles.
1. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77–93. 2. US Food and Drug Administration. EXONDYS 51 full prescribing information 2016. doi. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206488lbl.pdf . Accessed 17 Mar 2017. 3. McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, Heydemann P, Kaminska A, Kirschner J, Muntoni F0, Osorio AN, Schara U, Sejersen T, Shieh PB, Sweeney HL, Topaloglu H, Tulinius M, Vilchez JJ, Voit T, Wong B, Elfring G, Kroger H, Luo X, McIntosh J, Ong T, Riebling P, Souza M, Spiegel RJ, Peltz SW, Mercuri E; Alfano LN, Eagle M, James MK, Lowes L, Mayhew A, Mazzone ES, Nelson L, Rose KJ, Abdel-Hamid HZ, Apkon SD, Barohn RJ, Bertini E, Bloetzer C, de Vaud LC, Butterfield RJ, Chabrol B, Chae JH, Jongno-Gu DR, Comi GP, Darras BT, Dastgir J, Desguerre I, Escobar RG, Finanger E, Guglieri M, Hughes I, Iannaccone ST, Jones KJ, Karachunski P, Kudr M, Lotze T, Mah JK, Mathews K, Nevo Y, Parsons J, Péréon Y, de Queiroz Campos Araujo AP, Renfroe JB, de Resende MBD, Ryan M, Selby K, Tennekoon G, Vita G. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10101):1489–498. 4. Sarepta Therapeutics. Clinical trials: the basics and our clinical trials: a double-blind, placebo-controlled, multi-center study with an open-label extension to evaluate the efficacy and safety of SRP-4045 and SRP-4053 in patients with Duchenne muscular dystrophy 2017;2017. 5. ClinicalTrials.gov. Registry of Translarna (Ataluren) in nonsense mutation Duchenne muscular dystrophy: NCT02369731. 2017. doi. https://clinicaltrials.gov/ct2/show/NCT02369731 . Accessed 17 Mar 2017.
Cited by
78 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|